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ABSTRACT 
CRISPR-BASED KNOCKOUT SCREENING IN PRIMARY NEURONS 
Ben Callif 
Marquette University, 2017 
Axon growth is coordinated by multiple interacting proteins that remain incompletely 
characterized. High content screening (HCS), in which manipulation of candidate genes is 
combined with rapid image analysis of phenotypic effects, has emerged as a powerful technique 
to identify key regulators of axon outgrowth. Here we explore the utility of a genome editing 
approach referred to as CRISPR (Clustered Regularly Interspersed Palindromic Repeats) for 
knockout screening in primary neurons. In the CRISPR approach a DNA-cleaving Cas enzyme is 
guided to genomic target sequences by user-created guide RNA (sgRNA), where it initiates a 
double-stranded break that ultimately results in frameshift mutation and loss of protein 
production. Using electroporation of plasmid DNA that co-expresses Cas9 enzyme and sgRNA, 
we first verified the ability of CRISPR targeting to achieve protein-level knockdown in cultured 
postnatal cortical neurons. Targeted proteins included NeuN (RbFox3) and PTEN, a well-studied 
regulator of axon growth. Effective knockdown lagged at least four days behind transfection, but 
targeted proteins were eventually undetectable by immunohistochemistry in more than 80% of 
transfected cells. Consistent with this, anti-PTEN sgRNA produced no changes in neurite 
outgrowth when assessed three days post-transfection. When week-long cultures were replated, 
however, PTEN knockdown consistently increased neurite lengths. These CRISPR-mediated 
PTEN effects were achieved using multi-well transfection and automated phenotypic analysis, 
indicating the suitability of PTEN as a positive control for future CRISPR-based screening 
efforts. Combined, these data establish an example of CRISPR-mediated protein knockdown in 
primary cortical neurons and its compatibility with HCS workflows.
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I. INTRODUCTION 
As the name implies, Neuroscience is the study of neurons and the nervous system. 
However, within the field there seems to be a bias whereby researchers focus on either the brain 
or the body, while ignoring the interaction between these two inseparable systems. This is 
exemplified by the Society for Neuroscience which, per their website, is “the world’s largest 
organization of scientists and physicians devoted to understanding the brain and nervous system” 
(https://www.sfn.org/About/Mission-and-Strategic-Plan). This contrast between the brain and the 
nervous system is likely a reflection of the differentiation between the central (CNS) and 
peripheral nervous systems (PNS), which are distinguished by protective barriers that isolate the 
cerebrospinal fluid (CSF) from the blood. Unfortunately, this puts the spinal cord in a precarious 
position, since it is clearly a part of the CNS, but is almost entirely ignored in Neuroscience 
education. For example, the blood-brain barrier (BBB), which isolates the brain from the rest of 
the body, is a popular topic of research and teaching curriculums, but the blood-spinal cord 
barrier, which isolates the spinal cord from the blood, is rarely mentioned and is intuitively 
thought of by researchers as being synonymous with the BBB (Bartanusz et al., 2011).   
This theoretical separation between the brain and the nervous system in Neuroscience is 
unfortunate and unnecessary. The brain is undoubtedly a part of the nervous system – despite the 
isolation by the BBB, the brain and the body are intrinsically connected and neither functions 
without the other. The connection and interface between the brain to the body is mediated by the 
spinal cord: a long bundle of nerves extending from the base of the brain down to the pelvic 
region. The spinal cord receives information from the peripheral tissues of the body, like the skin, 
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muscles, and joints, and transmits this information to the brain where it is processed as sensory 
input and re-transmitted back to the spinal cord in the form of motor commands (Schwab, 2002). 
The focus on the brain as the centralized control center for the rest of the body and nervous 
system runs contrary to the thoughts of the great thinker, Leonardo da Vinci, who stated: “The 
frog instantly dies when the spinal cord is pierced; and previous to this it lived without head, 
without heart or any bowels or intestines or skin; and here therefore would seem lies the 
foundation of movement and life” (Lifshutz & Colohan, 2004). Although humans do not 
technically need a fully functional spinal cord to survive, the spinal cord is a necessary feature of 
vertebrate existence (Romer & Parsons, 1986).  
The spinal cord is the connection between the brain and the body, and spinal cord injury 
(SCI) is a perfect metaphor for the gap between Neuroscience and bodily physiology. The 
interruption of information flow from the periphery to the brain, and vice versa, is debilitating for 
bodily function, just like the theoretical distinction between studying the ‘brain’ and the ‘nervous 
system’ is holding back the field. Despite the exponential advances in the complexity of 
Neuroscientific research and our understanding of the brain there have been few, if any, effective 
cures for mental health disorders (Grohol, 2009). Neuroscience, the study of the brain to improve 
psychological well-being, is a relatively new field, but SCI has been studied for thousands of 
years and has a similar story. The first historical mention of SCI was in ancient Egypt in 2500 
BC, and a shortened translation of the papyrus reads: “If thou examines a man having a 
dislocation of the neck … thou shouldst say concerning him … an ailment not to be treated” 
(Lifshutz & Colohan, 2004). From this translation, we can see how it has taken over 4,000 years 
to advance medicine enough to even have hope for a cure to SCI.  To make Neuroscience more 
productive it will be necessary to metaphorically unify the relationship between the CNS and the 
rest of the body, much like it is necessary to bridge the literal gap between the brain and the body 
by healing the spinal cord to cure SCI. 
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SCI is broadly defined as a disruption of the spinal cord which causes changes in bodily 
function below the injury site. This definition is quite broad because the presentation of SCI is 
widely varied based on the magnitude, location, and cause of the injury. There are two major 
categories of injury to the spinal cord: complete and incomplete. These labels refer to the severity 
of the injury, with a complete injury causing a total loss of function and sensation below the 
injury site and an incomplete injury causing only a partial loss (Ho et al., 2007). Furthermore, SCI 
is also designated by the location of the injury site. Lumbro-sacral injuries occur near the base of 
the spine and can cause changes in the function of everything from the hips down. This can cause 
problems with the urogenital system and lead to a toxic buildup of urine due to loss of functional 
bladder control (O’Sullivan et al., 2014). Thoracic injuries occur in the abdominal region and 
affect the function of everything from the chest down. This can be a serious issue for sympathetic 
homeostatic controls like body temperature and blood vessel dilation which can lead to 
neurogenic shock which is characterized by blood pooling in the limbs, low blood pressure, and 
low heart rate (Holtz & Levi, 2010). Finally, cervical spinal cord injuries occur in the region of 
the neck and can affect the entire body leading to tetraplegia, or loss of function in all four limbs. 
This can cause all the problems previously mentioned for lumbro-sacral and thoracic sites of 
injury in addition to an extremely serious paralysis of the muscles that control breathing 
(Sabharwal, 2014). 
The consequences of SCI can be very severe, but luckily it has a relatively low 
prevalence. It is difficult to gauge the global impact of SCI, since the numbers vary drastically 
from country to country. For example, in Africa and many regions of Asia there is very little data 
to about the number of SCIs and the causes of the injuries (Witiw & Fehlings, 2015). However, in 
the United States approximately 12,000 people receive SCIs every year and in China there are 
nearly 60,000 new cases of SCI every year (Liu et al., 2015; Qiu, 2009). These may seem like 
low incidence rates, but in the United States there are up to 300,000 people living with a spinal 
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cord injury (Field-fote, 2009). This is a huge problem because with proper treatment these 
individuals can live a long time following their injuries and the medical costs are staggering. 
There are initial medical expenses that must be dealt with immediately following the injury, like 
surgery, rehab, and mobility equipment such as electric wheelchairs. There are also subsequent 
expenses for every year of life following the injury, since these patients may never entirely 
recover bodily function. These include follow-up surgeries and medical expenses related to 
complications from the injury as well as the cost of full or part-time caretakers, since SCI can 
cause a partial or total loss of mobility and self-reliance. For an incomplete injury, the first year 
can cost upwards of $300,000 and every year of life following the injury can cost up to $40,000. 
For a complete injury, the first year can cost anywhere from $500,000 up to $1,000,000 and each 
following year of life can cost anywhere from $60,000 to $180,000 (https://www.nscisc.uab.edu). 
The financial and physiological destruction that these injuries cause becomes even more apparent 
when the monetary costs are stacked on top of the debilitating nature of most SCIs and the 
inability of many SCI sufferers to continue working following their injury. The devastating nature 
of these injuries to everyday life is even more clear when patients are surveyed about how their 
lives could be enhanced: the top priority for quadriplegics was to simply regain arm and hand 
function, while paraplegics wanted to regain sexual function. All SCI patients agreed that a close 
second place for quality of life improvement would be simply having control over their bowels 
and bladders again (Anderson, 2004). 
Along with its high cost, SCI has many seemingly mundane causes that could happen to 
anyone. Physical trauma is the most likely way to receive an injury that disrupts the spinal cord 
(Peitzman et al., 2013). For example, some of the most common traumas that cause SCI are motor 
vehicle accidents and sports (Sabharwal, 2014). Depending on the geographic region falls and 
violence, like gunshot wounds, are also leading causes of SCI (Holtz & Levi, 2010). Although 
physical trauma is the leading cause, SCI can also occur due to degenerative diseases and 
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infections. Interestingly, in developing countries the most common causes of SCIs are infectious 
diseases like HIV and tuberculosis (Sabharwal, 2014). Compared to developing countries, people 
in developed countries have a higher chance of SCI due to degenerative conditions like multiple 
sclerosis and even due to diseases like meningitis and cancerous tumors which can cause damage 
by putting pressure on the spinal cord (New et al., 2014).  
Due to the severity of the injury, the high cost of living, and the variety of presentations 
of SCI there is research being done that attacks the problem from all angles. Since there are many 
people currently living with an SCI, much of the research is focused on how we can improve the 
quality of life and increase bodily function following an injury. For example, the best technology 
currently available for improving mobility and function following SCI essentially turns patients 
into cyborgs. Power wheelchairs allow for mobility without the use of the leg muscles or nursing 
aids and there are even wheelchairs that can be controlled with tongue motions to help individuals 
with complete tetraplegic injuries (Kim et al., 2013). Amazingly, some research has even started 
to utilize robotic exoskeletons as a method of rehabilitating and restoring function to paralyzed 
individuals (Aach, et al., 2014). Restoring function and rehabilitating injured individuals is a 
worthy goal, and while some patients spontaneously recover after an injury many patients will 
never fully regain function after SCI (Behrman & Harkema, 2000). Due to the role of the spinal 
cord as a bridge between brain function and bodily behavior one of the main goals of SCI 
research is to induce the regrowth of axons: the long projecting processes of neurons that encode 
outgoing information in the form of action potentials (Schwab, 2002; Waxman et al., 1995).  
One method of achieving this goal is to use exogenously applied agents to enhance the 
growth of the axons that compose the spinal cord. For example, many studies have focused on 
disrupting molecular signaling pathways that are inhibitory for growth, like the myelin associated 
Nogo-A. This has been attempted through application of Nogo-A neutralizing antibodies, which 
have shown promise for disinhibiting axonal regrowth in several animal models of SCI (Fouad et 
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al., 2004; Liebscher et al., 2005). Other studies have attempted to apply growth promoting agents 
to the injured cord to enhance axonal growth. Direct injections of hormones, such as 
progesterone, have been tested for neuroprotective effects following SCI (Thomas et al., 1999). 
There are also pumps available to constantly supply factors directly into the CSF, but a more 
popular method of growth factor application is implantation of genetically engineered cells, like 
fibroblasts, that produce and excrete specific factors into the injured spinal cord (McTigue et al., 
1998; Tuszynski et al., 2003). More recently, direct application of mitochondrial-targeted ceria 
nanoparticles has also emerged as a possible means of neuroprotection following SCI (Das et al., 
2007). 
In recent years, direct genetic modification of cortical neurons has become another 
method of coaxing axons to grow. The use of Adeno-associated viruses (AAVs) provides a 
straightforward and consistent method of expressing target genes with a relative amount of spatial 
specificity (Blackmore et al., 2012). Genetically modified animals have also been used to model 
the role that specific factors play in axonal regrowth following an injury (Sun et al., 2011). But 
there are some issues with this. For example, while direct application studies showed a role for 
factors such as Nogo-A in regeneration following SCI, there are conflicting reports about whether 
mutant mice altogether lacking Nogo-A mount a stronger regenerative response than naïve, wild-
type animals (Simonen et al., 2003; Zheng et al., 2003). Similarly, it is now clear that targeted 
manipulation of gene expression in injured neurons is an effective means to improve axon 
growth, but improvements remain partial and no studies have yet induced spinal cord 
regeneration to the point of actually growing axons past the injury site (Belin et al., 2015; 
Blackmore et al., 2012; Sun et al., 2011; Wang et al., 2015).  
These studies and others have shown that the growth of axons and dendrites depends on 
numerous cellular processes including cytoskeletal remodeling, membrane expansion, 
intracellular signaling, regulated transport, and transcription. Thus, the coordinated activity of 
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hundreds of proteins is needed for effective neurite extension. Identifying the full set of proteins 
that regulate axon growth remains a key objective in regenerative neuroscience and is critical for 
ongoing efforts to improve regenerative ability in neurons that have lost axons to injury or 
disease. Forward genetic screens performed in primary neurons have emerged as a powerful tool 
to discover novel regulators of neurite growth (Blackmore, 2012). These screens generally rely on 
two components. First, approaches such as electroporation or viral transduction in multi-well 
format are used to achieve high throughput genetic modification of primary neurons. Second, 
automated image analysis in multi-well format rapidly quantifies effects on neurite extension. 
This readout can be performed on the overall population of neurons (e.g. “well-based” 
quantification), or can assess neurite length from individual neurons (e.g. “cell-based” analysis). 
A variety of labs have now harnessed this genetic screening approach, leading to a rapid 
expansion of the set of known regulators of axon growth (Blackmore, 2012; Blackmore et al., 
2010; Buchser et al., 2012; Simpson et al., 2015; Zou et al., 2015).  
Many of these screens involve gene overexpression and thus address the sufficiency of 
ectopic gene expression to evoke phenotypic responses. For example, we in the Blackmore lab 
have previously performed an overexpression screen of 69 transcription factors (Simpson et al., 
2015). There are an overwhelming number of candidate factors we could have picked to include 
in the screen, so we decided to focus on transcription factors that are related to the development 
of cancer. The idea behind this was that neurons are post-mitotic, and therefore, cannot divide. 
We hypothesized that induction of a cancerous state in these cells would cause a phenotype 
somewhat like cancerous growth, but through the extension of neurite processes rather than cell 
division. This strategy turned out to be quite effective, as 9 of the 69 factors we overexpressed 
significantly altered the outgrowth of cortical neurites in culture. However, overexpression 
studies such as this one are only useful to delineate the complexities of systemic interaction with 
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exogenously applied factors. In order to clarify the role of endogenous protein in neurite 
outgrowth, knockout approaches are necessary (e.g. (Zou et al., 2015).   
 Genome editing methods such as zinc finger nucleases (ZFNs), Transcription Activator-
Like Effector Nucleases (TALENs), and Clustered Regularly Inter-Spaced Palindromic Repeats 
(CRISPR) represent potentially improved tools for knockout screening. Unlike previous RNAi 
approaches, which act post-transcriptionally and may induce only partial protein knockdown, 
genome editing can modify DNA at specific loci to abolish protein production completely and 
permanently. CRISPR, in particular, has been widely adopted and enthusiastically embraced by 
the public and the media. CRISPR is an emerging technique that avoids many of the problems 
associated with RNAi. The tool itself is borrowed from an adaptive immune system found in 
approximately 40% of bacterial genomes and almost all archaeal genomes (Kunin et al., 2007). 
CRISPR has evolved to recognize invading viral DNA and excise it from the host’s genome. It 
performs this complicated task through a series of nucleases known as the Cas (CRISPR-
associated) proteins.  
There are a variety of CRISPR/Cas systems, but they generally operate through the same 
principles. Briefly, the first Cas enzymes in the pathway recognize a short sequence of 
nucleotides in the viral DNA, known as a PAM (protospacer adjacent motif), that will never be 
expressed by the host. This PAM acts to ensure that the CRISPR/Cas system will not act upon 
any endogenous bacterial DNA sequences. The PAM, along with a consistent number of 
downstream nucleotides known as a spacer, is then removed from the invading DNA and inserted 
into a specific locus in the host’s genome. The spacer is placed into the genome in such a way 
that it is flanked on either side by palindromic repeats. This sequence of spacers and palindromic 
repeats is then transcribed into a single RNA molecule, which is further processed into short, 
single-stranded RNAs called CRISPR RNAs (crRNAs). The crRNA, along with a partially 
complementary tracrRNA (trans-activating crRNA), binds to the Cas9 enzyme creating a 
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ribonucleoprotein effector complex. Watson-Crick base pairing will ensue if this 
ribonucleoprotein complex encounters dsDNA (double-stranded DNA) that is complementary to 
its crRNA. Once the complex is tightly bound to the dsDNA Cas9 will recognize the PAM 
sequence upstream of the target sequence and induce a double-stranded break (Terns & Terns, 
2011).  
 The endogenous CRISPR system is quite complex, but a recent paper by Cong et al. 
(2013) showed that only a few pieces of the pathway are necessary to efficiently and accurately 
knock out targets at the genomic level. To simplify the way that the Cas9 enzyme handles RNA 
they created a crRNA/tracrRNA hybrid called sgRNA (short guide RNA). They showed that 
expression of the Cas9 enzyme and an sgRNA was sufficient to induce targeted double-stranded 
breaks with high specificity and efficiency. Without a template the double-stranded breaks are 
repaired by the highly error prone NHEJ (non-homologous end-joining machinery), which 
frequently causes indel (insertion or deletion) mutations. If the Cas9/effector complex is targeted 
to the ORF (open reading frame) of a gene the ensuing NHEJ repair will often cause a frameshift 
mutation due to indels, functionally knocking out the gene. Targeted genomic knock out is 
extremely useful, but it only begins to scratch the surface of CRISPRs capabilities. It is now well 
established that Cas proteins are functional when expressed in mammalian cells and can be 
directed to specific loci by supplying nothing more than an sgRNA targeting a user-specified 
gene. Importantly, examples now exist to demonstrate the efficacy of protein-level knockout by 
the CRISPR strategy in neurons (Platt et al., 2014; Straub et al., 2014; Swiech et al., 2015; 
Zuckermann et al., 2015). 
There may be unique challenges, however, to adopting the CRISPR approach to 
screening in post-mitotic neurons. First, previous CRISPR-based screens in non-neuronal cells 
have relied on purifying and expanding affected cells with antibiotic resistance genes or 
fluorescent reporters to obtain knockout clones (An et al., 2014; Chen et al., 2015; Schmid-Burgk 
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et al., 2016; Wang et al., 2014). Without the option of proliferation-based purification, however, 
gene delivery methods for neurons must be rapid and efficient. Second, no studies have yet 
determined how quickly CRISPR causes knockdown in neurons. There must be a defined 
timecourse of knockdown to rationally plan experimental endpoints. Finally, the few publications 
that have utilized CRISPR in cultured neurons have used lentiviral-based approaches to force 
expression of a Cas enzyme and an sgRNA (Incontro et al., 2014; Telese et al., 2015). Large-
scale screening, however, may be more feasible and economical using plasmid-based transfection 
(Ebert et al., 2008; Moffat et al., 2006; Root et al., 2006). 
Here we propose to perform validation and optimization experiments to assess the utility 
of CRISPR for high content screening in neurons. Using delivery of Cas9 and sgRNA by plasmid 
electroporation in multi-well format, we will confirm the timecourse of protein knockdown using 
a previously validated targeting sequence for NeuN (Rbfox3), a ubiquitously expressed neuronal 
protein (Platt et al., 2014). We will next deliver sgRNA against Phosphatase and Tensin homolog 
(PTEN), a well-studied inhibitor of neurite outgrowth. Initial data suggests that for both targets 
the majority of transfected neurons will not be affected by CRISPR knockdown until after 3 days 
in vitro. By this point the neurons in the culture have created an extensive web of synaptic 
connections, which makes neurite outgrowth analysis difficult, if not impossible. Therefore, we 
also propose to create and optimize a replating technique, which will either mechanically or 
enzymatically disentangle neurons from the plate they were initially cultured in so that we can 
remove the cells and re-culture them on a new plate. We hope to use this replating technique in 
conjunction with our neurite outgrowth assay to validate a positive control for future screens. 
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II. THE APPLICATION OF CRISPR TECHNOLOGY TO HIGH CONTENT SCREENING IN 
PRIMARY NEURONS 
Background 
The growth of axons and dendrites depends on numerous cellular processes including 
cytoskeletal remodeling, membrane expansion, intracellular signaling, regulated transport, and 
transcription. Thus, the coordinated activity of hundreds of proteins is needed for effective neurite 
extension. Identifying the full set of proteins that regulate axon growth remains a key objective in 
regenerative neuroscience and is critical for ongoing efforts to improve regenerative ability in 
neurons that have lost axons to injury or disease. For instance, it is now clear that targeted 
manipulation of gene expression in injured neurons is an effective means to improve axon growth 
(Belin et al., 2015; Blackmore et al., 2012; Sun et al., 2011; Wang et al., 2015). Improvements 
remain partial, however, motivating the search for additional regulatory proteins that might act as 
therapeutic targets.  
 Forward genetic screens performed in primary neurons have emerged as a powerful tool 
to discover novel regulators of neurite growth (Blackmore, 2012). These screens generally rely on 
two components. First, approaches such as electroporation or viral transduction in multi-well 
format are used to achieve high throughput genetic modification of primary neurons. Second, 
automated image analysis in multi-well format rapidly quantifies effects on neurite extension. 
This readout can be performed on the overall population of neurons (e.g. “well-based” 
quantification), or can assess neurite length from individual neurons (e.g. “cell-based” analysis). 
A variety of labs have now harnessed this genetic screening approach, leading to a rapid 
expansion of the set of known regulators of axon growth (Blackmore, 2012; Blackmore et al., 
2010; Buchser et al., 2012; Simpson et al., 2015; Zou et al., 2015). Many of these screens involve 
gene overexpression and thus address the sufficiency of ectopic gene expression to evoke 
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phenotypic responses. To clarify the role of endogenous protein in neurite outgrowth, however, 
knockout approaches are necessary (e.g. (Zou et al., 2015).   
 Genome editing methods such as zinc finger nucleases (ZFNs), Transcription Activator-
Like Effector Nucleases (TALENs), and Clustered Regularly Inter-Spaced Palindromic Repeats 
(CRISPR) represent potentially improved tools for knockout screening. Unlike previous RNAi 
approaches, which act post-transcriptionally and may induce only partial protein knockdown, 
genome editing can modify DNA at specific loci to abolish protein production completely and 
permanently. CRISPR in particular has been widely adopted. CRISPR evolved as a bacterial 
adaptive immune system in which Cas (CRISPR-associated) nucleases are directed to degrade 
foreign DNA (Kunin et al., 2007). DNA binding by Cas nucleases is limited to sequences 
adjacent to a specific 3-nucleotide protospacer adjacent motif (PAM) (Terns and Terns, 2011). 
Critically, Cas nucleases are guided to specific PAM-adjacent regions by RNAs that are 
complementary to the target DNA sequence. It is now well established that Cas proteins are 
functional when expressed in mammalian cells and can be directed to specific loci by supplying 
RNA sequences called single-guide (sgRNA) that contain a user-designed targeting domain. Cas 
nucleases initiate double-stranded breaks followed by error prone non-homologous end-joining 
(NHEJ), resulting in insertion or deletion mutations that disrupt the production of functional 
protein when directed to coding regions. Importantly, examples now exist to demonstrate the 
efficacy of protein-level knockout by the CRISPR strategy in neurons (Platt et al., 2014; Straub et 
al., 2014; Swiech et al., 2015; Zuckermann et al., 2015). 
There may be unique challenges, however, to adopting the CRISPR approach to 
screening in post-mitotic neurons. First, previous CRISPR-based screens in non-neuronal cells 
have relied on purifying and expanding affected cells with antibiotic resistance genes or 
fluorescent reporters to obtain knockout clones (An et al., 2014; Chen et al., 2015; Schmid-Burgk 
et al., 2016; Wang et al., 2014). Without the option of proliferation-based purification, however, 
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gene delivery methods for neurons must be rapid and efficient. Second, no studies have yet 
determined how quickly CRISPR causes knockdown in neurons. There must be a defined 
timecourse of knockdown in order to rationally plan experimental endpoints. Finally, the few 
publications that have utilized CRISPR in cultured neurons have used lentiviral-based approaches 
to force expression of a Cas enzyme and an sgRNA (Incontro et al., 2014; Telese et al., 2015). 
Large-scale screening, however, may be more feasible and economical using plasmid-based 
transfection (Ebert et al., 2008; Moffat et al., 2006; Root et al., 2006). 
Here we performed validation and optimization experiments to assess the utility of 
CRISPR for high content screening in neurons. Using delivery of Cas9 and sgRNA by plasmid 
electroporation in multi-well format, we first confirmed the timecourse of protein knockdown 
using a previously validated targeting sequence for NeuN (Rbfox3), a ubiquitously expressed 
neuronal protein (Platt et al., 2014). We next designed and delivered sgRNA against Phosphatase 
and Tensin homolog (PTEN), a well-studied inhibitor of neurite outgrowth. For both targets the 
majority of neurons were unaffected by CRISPR knockdown until 4 to 6 days post-transfection 
and during this time they extended lengthy processes that were not amenable to neurite outgrowth 
analysis. Therefore, we developed a replating approach to disentangle overgrown neurites. 
Following replating automated microscopy was able to detect a robust outgrowth phenotype from 
PTEN knockout, thereby establishing a positive control for CRISPR-based phenotypic screening. 
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Results 
Time course of CRISPR-mediated knockout of target proteins in primary cortical neurons 
 CRISPR has been extensively used to decrease protein expression in mitotically active 
cells and recently, knockdown in post-mitotic neurons has been achieved. For example, an 
sgRNA targeting sequence against neuron-specific NeuN was shown to reduce NeuN protein 
expression in adult cortical neurons in vivo upon transgenic co-expression of spCas9 (Platt et al., 
2014). We therefore asked whether this same targeting sequence affected NeuN expression in 
primary cortical neurons that were transfected to express spCas9 and, if so, over what time 
course.  The validated anti-NeuN targeting sequence was cloned into the Px330 plasmid, which 
co-expresses spCas9 and sgRNA (Cong et al., 2013). Using previously established techniques, 
plasmid was then delivered by electroporation to cortical neurons prepared from postnatal (P3-
P5) rat pups (Blackmore et al., 2010; Buchser et al., 2006). To identify transfected cells, an EGFP 
reporter was co-transfected at a 1:4 ratio, a strategy shown previously to result in >90% co-
expression of test plasmid and reporter (Blackmore et al., 2010). Neurons were plated at high 
density (100,000 cells plated per well in 24-well format) in media containing 5-Fluoro-2’-
deoxyuridine (FuDR) to limit glial proliferation, and then fixed every two days between 4 and 14 
days in vitro (DIV). Then, NeuN immunofluorescence was quantified in transfected neurons, 
which were identified by EGFP and immunohistochemistry for neuron-specific ΒIII-tubulin (Fig. 
1A-C). After 4 days, a significant but modest decrease in average NeuN immunofluorescence was 
detected in anti-NeuN treated cells compared to control cells transfected with SpCas9 and non-
targeted sgRNA (Fig. 1D). Importantly, only 20% of anti-NeuN treated cells showed NeuN levels 
that fell below a threshold set by the dimmest 5% of control cells. Two days later, however, anti-
NeuN displayed a larger reduction in average NeuN immunofluorescence, and more than 50% of 
transfected cells were dimmer than the lowest 5% of control cells. Later time points showed a 
trend toward lower NeuN expression, with more than 75% of transfected cells dimmer than 95% 
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of control cells (Fig. 1D). These data confirm that CRISPR-mediated knockout of NeuN is 
effective in cultures of primary cortical neurons, but requires approximately a week to strongly 
affect a majority of transfected neurons.   
 
 
Figure 1. CRISPR effectively decreases NeuN protein levels in primary neurons. P3-P5 cortical neurons 
were transfected with plasmid DNA co-expressing spCas9 and anti-NeuN or non-targeted sgRNA. Neurons were 
cultured, fixed between 4 and 14 days in vitro (DIV), and immunostained for neuron-specific βIII tubulin and 
NeuN. (A-C) show anti-NeuN treated neurons 14 days after transfection. EGFP (B) identifies transfection 
(arrow).  (C) Immunohistochemistry detects NeuN protein in a EGFP-negative neuron (arrowhead), but not in 
a transfected neighbor (arrow). (D) Each dot represents NeuN immunofluorescence intensity in a single 
transfected (EGFP+) neuron between 4DIV and 14DIV. Grey boxes indicate a threshold set by the dimmest 5% 
of control-transfected neurons at each timepoint, and the percent of anti-NeuN cells that fall below that threshold 
is quantified above. Significant differences existed between the population-level average intensity at all 
timepoints (p=0.033 4DIV, p=7.4x10-9  6DIV, p=1.8x10-8  8DIV,  p=3.7x10-5  10DIV, p=1.6x10-7  12DIV, 
p=7.9x10-12  14DIV; unpaired t-test), and the percent of anti-NeuN cells below threshold increases between 4 
and 6DIV. N=40 cells per group per timepoint. 
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 We next sought to determine the efficacy and time course of CRISPR-based knockout of 
a second protein, which had not previously been targeted with a CRISPR approach. We selected 
PTEN for knockdown based on its well-established role in neurite outgrowth in other types of 
neurons (reviewed in Ohtake et al., 2015). Using publicly available algorithms to maximize 
selectivity and efficacy (Doench et al., 2014; Hsu et al., 2013), short oligonucleotides containing 
anti-PTEN targeting sequences were synthesized, annealed, and ligated into the PX330 plasmid 
(Cong et al., 2013). As before, P3-P5 rat cortical neurons were electroporated with 4 µg of  anti-
PTEN or control PX330 plasmid and plated in FuDR-treated media, then fixed every 2 days 
starting at 4DIV and ending at 14DIV. Neurons were identified by immunohistochemistry for 
NeuN and transfected cells were identified by the expression of EGFP (Fig. 2A-C). PTEN 
expression was manually quantified by drawing a region of interest around the cell body of 
transfected neurons and recording average PTEN immunofluorescence, as measured by NIS-
elements software. Four days after transfection, average PTEN fluorescence was significantly 
reduced in the anti-PTEN group, and 67% of transfected neurons fell below the dimmest 5% of 
control neurons. Two days later, average PTEN fluorescence was further reduced in the anti-
PTEN group, and 85% of neurons fell below the 5% threshold (Fig. 2D). Thus, user-designed 
CRISPR targeting sequences effectively decreases protein expression of PTEN in primary 
cortical neuron cultures on a time scale of four to six days. 
 One potential strategy to accelerate protein knockdown may be to use multiple sgRNAs 
that target discrete coding regions of the same gene. To test this possibility, four sgRNA 
sequences against PTEN were designed and delivered singly or in pair-wise combinations to early 
postnatal cortical neurons. In order to facilitate comparison with established shRNA-based 
approaches, cells were transfected with anti-PTEN shRNA shown previously to be effective in 
CNS neurons (Yungher et al. 2015). Cells were maintained between 2 and 14 days in culture, 
fixed, and visualized with immunohistochemistry against PTEN and neuron-specific βIII tubulin.  
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In contrast to the manual quantification performed above, in this experiment we utilized a 
Cellomics high content screening microscope to assess PTEN intensity, which enabled analysis of 
hundreds of cells per treatment at each timepoint. In this analysis, the 10% of cells with the 
brightest EGFP signal were quantified, in order to focus the analysis on effectively transfected 
Figure 2. CRISPR effectively decreases PTEN protein levels in primary neurons. P3-P5 cortical neurons 
were transfected with plasmid DNA co-expressing spCas9 and anti-PTEN or non-targeted sgRNA. (A-C) show 
neurons, identified by NeuN (A), 14 days after transfection with anti-PTEN. (B) EGFP identifies transfection 
(arrow). (C) Immunohistochemistry detects PTEN protein in a EGFP-negative neuron (arrowhead), but not in a 
transfected neighbor. (D) Each dot represents PTEN immunofluorescence intensity in a single transfected 
(EGFP+) neuron between 4DIV and 14DIV. Grey boxes indicate a threshold set by the dimmest 5% of control-
transfected neurons at each timepoint, and the percent of anti-PTEN cells that fall below that threshold is 
quantified above. Significant differences existed between the population-level average intensity at all timepoints 
(p=6.9x10-11  4DIV, p=1.4x10-8  6DIV, p=5.0x10-13  8DIV,  p=3.3x10-15  10DIV, p=4.8x10-14  12DIV, p=3.7x10-
17  14DIV; unpaired t-test), and by 6DIV 85% of anti-PTEN treated cells fell below the 5% threshold. N=40 cells 
per group per timepoint. 
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neurons. In support of this, we found that reduction in PTEN expression was greatest in the top 
10% of EGFP-expressing cells (Fig. 3). As shown in Figure 4, all four anti-PTEN sgRNA 
sequences produced significant knockdown of PTEN in transfected neurons. Consistent with the 
previous manual quantification, the percent of neurons with PTEN intensity below the 5% control 
threshold increased from 8-10% at 2DIV to 51-66% at 14DIV. Mixtures of two sgRNAs did not 
accelerate the onset of knockdown or increase the percent of affected cells at later timepoints. 
Interestingly, knockdown of PTEN protein via shRNA was much more rapid, with 58% of cells 
below the 5% threshold after only 2DIV. Overall, these data confirm a lag in the onset of protein 
knockdown by Cas9 compared to shRNA. Moreover, combined sgRNA sequences did not 
shorten this lag.  
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Figure 3. The degree of CRISPR-mediated knockdown of PTEN correlates with EGFP-reporter intensity. 
P3-P5 cortical neurons were co-transfected with EGFP reporter plasmid and plasmid co-expressing spCas9 and 
one of four distinct sgRNA sequences targeting PTEN labeled in the figure as PTEN A-D, or non-targeting 
sgRNA labeled in the figure as ‘PX330’ (See ‘Chapter III: Methodology’ for specific nucleotide sequences). At 
14 days post-transfection cells were fixed and immunostained for PTEN and Cellomics automated microscopy 
quantified immunofluorescence and EGFP reporter intensity. Then, the PTEN fluorescence of all cells was 
binned by EGFP intensity to determine the relationship between the fluorescence of the transfection marker and 
the level of PTEN knockdown. In all anti-PTEN sgRNA treatments 10% of cells with the brightest EGFP signal 
show a large and consistent reduction in PTEN fluorescence compared to the non-targeting control treatment 
(p<.001, ANOVA with post-hoc Dunnett’s). 
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Functional testing CRISPR-mediated phenotype in an 
HCS workflow 
 Having established effective CRISPR-mediated 
protein reduction in primary neurons, we next asked 
whether this approach could yield reproducible effects on 
neurite outgrowth using approaches compatible with HCS 
screening. Previous screens have utilized plasmid electroporation and culture in multi-well 
Figure 4. Four distinct anti-PTEN 
CRISPR constructs display similar 
timecourse of protein knockdown, 
which is delayed compared to shRNA-
mediated knockdown. P3-P5 cortical 
neurons were co-transfected with EGFP 
reporter and plasmid co-expressing 
spCas9 and one of four distinct sgRNA 
sequences targeting PTEN labeled in the 
figure as PTEN A-D, or mixtures of two 
sequences B+C and A+D. In parallel, 
neurons were also transfected with anti-
PTEN shRNA. Between 2 and 14 days 
later, cells were fixed and immunostained 
for PTEN protein, and Cellomics 
automated microscopy was used to 
quantify immunofluorescence in EGFP+ 
cells. (A) shows example histograms 
comparing PTEN immunofluorescence in 
populations of neurons transfected with 
anti-PTEN sgRNA and non-targeting 
control. At two days post-transfection the 
populations mostly overlap, but in 
subsequent days the percent of cells with 
low PTEN expression increases in the 
sgRNA treatment. Vertical lines indicate 
a threshold of PTEN signal set by the 
dimmest 5% of control cells. (B) 
quantifies the percent of EGFP+ cells 
with PTEN intensity below threshold at 
the same timepoint. At two days post-
transfection, single and mixed sgRNA-
treated populations display only 5% of 
cells below this threshold, while >50% of 
shRNA-treated cells fall below threshold. 
By six days, between 40 and 50% of 
sgRNA-treated cells fall below threshold. 
More than 500 cells were analyzed in 
each treatment at each timepoint.  
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format, followed by automated image acquisition and quantification of neurite outgrowth with 
Cellomics instrumentation (Blackmore et al., 2010; Simpson et al., 2015). This endpoint analysis 
is typically performed no more than three days in culture, after which time extensive overlap of 
neurites makes cell-based quantification very difficult. Although the previous timecourse data 
suggested it might be unlikely that phenotypic effects of CRISPR-mediated knockdown would be 
detectable within three days of transfection, we nevertheless tested the effects of anti-PTEN 
sgRNA using this lab standard protocol. As before, P4 cortical neurons were transfected with 
PX330-based plasmids encoding spCas9 and non-target, anti-PTEN, or anti-NeuN sgRNA as well 
as an EGFP reporter at a 1:4 ratio. Neurons were then cultured on PDL/laminin substrate for three 
days, fixed and stained with neuron-specific ΒIII tubulin, and neurite lengths quantified in 
transfected neurons. As shown in Figure 5, neurite length in cells transfected with anti-PTEN   
Figure 5. Short-term treatment with anti-PTEN CRISPR does not affect neurite length in primary cortical 
neurons. P3-P5 cortical neurons were transfected with plasmid DNA co-expressing spCas9, anti-NeuN, anti-PTEN 
or non-targeting sgRNA, along with plasmid encoding EGFP reporter. (A-I) Example images from ThermoScientific 
Cellomics CX5 high content screening platform. Neurons are identified by βIII-tubulin (A,D,G) transfection by 
EGFP (arrows, B,E,H), and neurite are traced (C,F,I) using βIII-tubulin fluorescence (J) Quantification of total 
neurite length shows no significant differences between any groups (p>.05, matched pair t-test with Bonferroni’s 
correction). N>100 cells per group in three replicate experiments. 
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sgRNA did not differ significantly from anti-NeuN or non-target controls.  
One possible explanation for these negative results is that during the first three days post-
transfection the degree of protein reduction was insufficient to affect neurite lengths. To test this 
possibility we adopted a strategy of maintaining longer term, high-density cultures, followed by 
replating. As before, P3-5 cortical neurons were transfected in multi-well format, but were plated 
and maintained at a relatively high density (100,000 cells plated per well in 24-well format) for 
seven days. As a positive control, additional cells were transfected with plasmid to overexpress 
Jun, shown previously to enhance neurite outgrowth in this cell type (Lerch et al., 2014; Simpson 
et al., 2015). FuDR was added to the media to block glial proliferation, resulting in more than 
95% pure neuronal cultures. After seven days, neurons were dissociated with Accutase and 
replated at a density of 10,000 cells per well on PDL/laminin substrates. After 24 hours of neurite 
extension the replated neurons were fixed, stained with ΒIII tubulin, and analyzed with Cellomics 
instrumentation as above (Fig. 6A-I). Although this procedure resulted in significant cell death, 
several hundred transfected neurons survived and extended neurites that were readily quantified. 
JUN overexpression enhanced neurite outgrowth by an average of 33.5% (±12.8% SEM) across 
three replicate experiments, similar to the 26.2%  (±6.9% SEM) seen in previous short-term 
screening experiments (Fig. 6J) (Simpson et al., 2015). These data confirm the sensitivity of this 
replating approach for detection of known growth phenotypes. In replated neurons treated with 
anti-PTEN sgRNA, neurite lengths were significantly elevated compared to non-targeted controls 
across four replicate experiments (136.8 ±8.0% SEM, p<.01, ANOVA with post-hoc Dunnett’s) 
(Fig. 6J). Immunohistochemistry for PTEN protein in the replated neurons confirmed effective 
knockdown, as 75% of cells fell below the threshold set by the dimmest 5% of control neurons 
(Fig. 7).  These data indicate that reduction of PTEN expression in early postnatal cortical 
neurons results in increased neurite lengths.  
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Figure 6. CRISPR-mediated knockdown of PTEN increases neurite length at a 7DIV timepoint. P3-P5 
cortical neurons were transfected with plasmid DNA expressing Jun or spCas9 and sgRNA (anti-PTEN or non-
targeting sgRNA), along with plasmid EGFP reporter. (A-I) show example images from ThermoScientific 
Cellomics CX5 high content screening platform. The automated microscope identifies neurons by βIII-tubulin 
(A,D,G) and transfection by EGFP (arrows) (B,E,H). CellInsight Cell Analysis software then automatically traces 
neurites (C,F,I) using the βIII-tubulin fluorescence. Compared to non-targeted sgRNA control (A,B,C,), increases 
in neurite length of transfected cells are apparent after Jun overexpression (D,E,F) or PTEN knockout (G,H,I). 
(J) Quantification of total neurite length shows significant increases in neurons treated with Jun overexpression 
and anti-PTEN sgRNA (p<.05, matched pair t-test with Bonferonni’s correction). N≥100 cells in 3 experimental 
replicates. (K) In a separate experiment, neurons were transfected with four distinct anti-PTEN sgRNA sequences, 
or pairwise combinations, maintained 7DIV, and then replated. 24 hours later, Cellomics-based quantification 
showed that three constructs caused significant increases in total neurite length, and the fourth showed a similar 
trend. P<.05, ANOVA with post-hoc Dunnett’s, N>500 cells per treatment.   
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It is possible that increased neurite outgrowth produced by treatment with anti-PTEN 
CRISPR sequences could result from off-target effects. Although off-target mutations can be 
detected through approaches like next-generation sequencing, a more practical solution in a 
screening experiment is to employ multiple targeting sequences against distinct regions of the 
same gene. Because different sgRNA constructs are unlikely to affect common off-target 
sequences, consistency of the evoked phenotype increases confidence that on-target knockdown 
explains the  observed effects. Indeed, we found that three of the four validated anti-PTEN 
sgRNA sequences significantly increased neurite length compared to non-specific sgRNA 
Figure 7. CRISPR-mediated decreases in PTEN expression persist following replating at 7DIV. P3-P5 cortical 
neurons were transfected with plasmid DNA co-expressing spCas9 and anti-PTEN or non-targeting sgRNA, along 
with plasmid EGFP reporter. (A-D) Show example image of replated cortical neurons. (A) Brightfield shows two 
neurons extending neurites 24 hours following replating. (B) EGFP identifies transfection (arrow). (C) 
Immunohistochemistry detects PTEN protein in an EGFP-negative neuron (arrowhead), but not in a transfected 
neighbor (arrow). (D) DAPI staining identifies both objects as nuclei containing cells (E) Each dot represents PTEN 
immunofluorescence intensity in a single transfected (EGFP+) neuron at 7DIV plus 24 hours post-replating. Grey 
boxes indicate a threshold set by the dimmest 5% of control-transfected neurons, and the percent of anti-PTEN cells 
that fall below that threshold is quantified above. Anti-PTEN sgRNA induces a significant reduction in the 
population average PTEN intensity (p=2.5x10-13, unpaired t-test), with 75% of cells below threshold. N=40 cells per 
group. 
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(p<0.05, ANOVA with post-hoc Dunnett’s), and the fourth sequence displaying a similar trend 
(Fig. 6K). Thus it is most likely that CRISPR-mediated knockdown of PTEN protein, as opposed 
to off-target effects, was responsible for the increased neurite length.  Importantly, these data also 
provide positive control sequences for CRISPR-mediated effects on neurite outgrowth, laying 
critical groundwork for the establishment of CRISPR-based screening approaches in primary 
neurons.  
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Discussion 
 We have assessed the suitability of CRISPR-based genome editing for use in phenotypic 
screening in primary neurons. Using cultured cortical neurons, we have established the time 
course and efficacy of CRISPR knock down for two proteins, NeuN and PTEN. We also 
established a replating technique for postnatal cortical neurons in order to assay neurite outgrowth 
when an extended period in culture is required. Finally, we show that CRISPR-based knockout of 
PTEN, delivered by electroporation in multiwell format, causes an increase in neurite outgrowth 
that is readily detectable by an automated screening platform. Overall, these results demonstrate 
the feasibility of performing a CRISPR-based high content knockout screen. 
The role of PTEN in early postnatal neurite outgrowth 
 PTEN, an upstream inhibitor of PI3K signaling and the mTOR pathway, was selected for 
this validation study because it has been shown to act in a variety of cell types as a negative 
regulator of axon extension. For example, transgenic knockout and shRNA-mediated knockdown 
of PTEN cause increased regenerative axon growth in retinal ganglion cells (Park et al., 2008; 
Yungher et al., 2015), corticospinal tract neurons (Liu et al., 2010; Zukor et al., 2013), 
rubrospinal neurons (Geoffroy et al., 2016), and dorsal root ganglion neurons (Christie et al., 
2010). The timing of knockdown appears to affect the rate of axon extension triggered by PTEN 
ablation, with stronger regenerative responses observed when PTEN is pre-ablated early in 
postnatal development and injuries performed after maturation (Geoffroy et al., 2016). Indeed, 
despite the clear role for PTEN in limiting axon growth in adult CNS neurons, it was previously 
unclear whether PTEN is similarly inhibitory in the cellular context of immature neurons, which 
possess a higher innate growth ability and lower levels of endogenous PTEN. The current data 
clearly indicate that PTEN is present in cortical neurons during early postnatal periods, and that 
PTEN ablation increases total neurite extension.  
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Challenges and unanswered questions 
An important question for any knockdown approach is the degree of specificity. In the 
case of CRISPR, knockout of off-target proteins by sgRNA could potentially produce phenotypic 
changes, leading to false positive screening results. Cleavage efficiency by CRISPR is strongly 
reduced by mismatches in the 20nt sgRNA/DNA binding site, particularly if multiple mismatches 
are located in PAM-proximal region (Hsu et al., 2013). Publically available algorithms now exist 
to scan genomes and identify sgRNA sequences with minimized potential for off-target cleavage; 
the sequences used here utilized the method of (Hsu et al., 2013). Nevertheless, the potential 
remains for off-target DNA cleavage, and a variety of techniques have been developed in non-
neuronal cells to detect them (reviewed in (Wu et al., 2014). For example, potential off-target 
sequences in the genome can be PCR-amplified and sequenced or analyzed by mismatch-specific 
nucleases (e.g. Surveyor). The most comprehensive approach is to perform whole genome 
sequencing of cell populations clonally derived from single sgRNA-treated cells (Smith et al., 
2014; Veres et al., 2014). Genome-wide sequencing is likely not feasible in individual post-
mitotic neurons, and even PCR-based analysis of predicted off-target cleavage is likely 
impractical for most screening projects. Thus, the best safeguard against off-target, false-positive 
hits will likely be to test multiple sgRNA sequences against the same protein target, similar to the 
strategy adopted by previous RNAi screens (Nieland et al., 2014; Sharma et al., 2013; Welsbie et 
al., 2013). Importantly, our data indicate that in the case of PTEN knockdown, three of four 
sgRNA targeting sequences produced a significant increase in neurite length. Setting 
requirements for consistent phenotype across multiple targeting sequences greatly increases the 
probability that on-target effects are responsible. 
Several groups have shown that RNAi approaches can cause non-specific effects through 
an innate immune response resulting in the expression of interferon proteins (Bridge et al., 2003; 
Sledz et al., 2003). Of particular relevance, delivery of lentiviral-mediated delivery of shRNA to 
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primary neurons has been shown to elevate expression of interferon-stimulated genes such as 
Oas1, with attendant decreases in viability and neurite outgrowth (Bauer et al., 2009; Hutson et 
al., 2012). Incorporation of microRNA flanking sequences and designs that prevent the formation 
of perfect double stranded RNA helixes have been used to alleviate this interferon response 
(Bauer et al., 2009; Cullen, 2006). It is unknown whether Cas9 and sgRNA induce a similar 
interferon, although the single-stranded nature of the sgRNA may make it less likely. 
Nevertheless, in future work it will be important to directly test for interferon responses and other 
potential non-specific effects of CRISPR.  
Another potential challenge is presented by the finding that CRISPR-mediated 
knockdown can take up to six days to affect the majority of transfected cells. After plasmid 
transfection, protein knockout can occur only after 1) production of Cas9 enzyme and sgRNA 2) 
Cas9-mediated cleavage at both genomic copies of PTEN and 3) clearance of existing protein 
pools. Which step contributes most to the six-day delay? We observe plasmid-driven expression 
of reporter proteins within 16 hours of transfection, making it unlikely that delayed expression of 
Cas9 protein is a major culprit. Similarly, the half-life of PTEN has been estimated at about 7.5 
hours (Trotman et al., 2007), and using shRNA we observe knockdown that is strong at 2DIV and 
nearly complete by 4DIV (Fig. 4), consistent with previous use of this shRNA targeting sequence 
(Yungher et al., 2015). Thus, a slow rate of PTEN turnover is also unlikely to explain the delay. 
Combined, these observations suggest a model in which DNA cleavage by Cas9 is a stochastic 
event that affects an expanding fraction of the population over the course of several days. 
Expanded experimentation is needed to confirm that a six day lag to knockdown is a general 
feature of the CRISPR strategy in primary neurons. Nevertheless, it is notable that we observed 
very similar timecourses for five distinct sgRNAs against two protein targets. Thus potential users 
should be alert to the possibility that screens involving CRISPR manipulation of primary neurons 
may require approximately a week in culture to achieve protein knockdown in a majority of 
29 
 
 
transfected cells, followed by additional time in culture for the phenotypic consequences to 
manifest. 
One consideration is that the timing of knockout may vary between individual cells 
(i.e.Cas9 cleavage may have affected some cells at 2DIV, others not until 6DIV). This range of 
time-since-knockout could act as a source of phenotypic variability. In addition, the lag between 
transfection and protein knockout may present a technical hurdle for some endpoint 
measurements, including screens of neurite outgrowth considered here. Indeed, we empirically 
tested and ruled out the possibility that CRISPR-based approach might be compatible with 
previous HCS workflows, in which neurite outgrowth was quantified at a 3DIV timepoint 
(Blackmore et al., 2010). We therefore adopted a replating technique, similar to procedures that 
we and others have used previously to disentangle dorsal root ganglion (DRG) neurons after 
extended culture (Simpson et al., 2015; Zou et al., 2009). This approach is feasible but introduces 
an extra step into the workflow and results in significant cell death, which increases the number 
of cells needed for the initial transfection step. In addition, the replating procedure likely 
introduces an increase in variability in subsequent neurite outgrowth, potentially reducing screen 
sensitivity. Indeed, when compared to prior data from non-replated neurons, we find a significant 
increase in variance of neurite length (standard deviation approximately 25% higher, f-test 
p<.01). Despite these caveats, however, this approach did produce consistent enhancement of 
neurite outgrowth after JUN overexpression and CRISPR-mediated PTEN knockout. The 
establishment of a consistent positive control is a promising step toward the use of CRISPR 
knockout in neurite outgrowth screens.  
Now that we have established positive controls it will be important to reduce variability 
and increase the sensitivity of future screens. One source of variability is imperfect co-
transfection between separate Cas9 and EGFP plasmids, although our previous data predict a 
greater than 90% co-expression at the 1:4 ratios used here (Blackmore et al. 2010). The PX330 
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vector we tested here does not include a reporter, and the large size of Cas9 creates challenges for 
reporter co-expression from a single plasmid. As a potential future solution, CRISPR technology 
allows for targeted homology-directed repair (HDR) (Cong et al., 2013). In this way a repair 
template containing either a fluorescent reporter or an antibiotic selection marker could be 
inserted when a target gene is nicked by Cas9. In principle, this approach would specifically 
identify cells affected by Cas9 enzyme. Challenges to this strategy include the fact that HDR has 
an extremely low efficiency, and the difficulty in distinguishing homozygous from heterozygous 
insertion, which could leave one copy of the target gene intact (Maruyama et al., 2015). 
Nevertheless, as CRISPR technologies rapidly evolve, HDR-based strategies may become more 
practical in a HCS environment. 
Future prospects for CRISPR-based screening in primary neurons 
One factor that may favor the adoption of CRISPR-based screening is the simplicity of 
creating effective reagents. In the current study, publically available algorithms were used to 
design targeting sequences ranked on the basis of specificity and efficacy. Following procedures 
described in (Cong et al., 2013), short oligonucleotides were synthesized, annealed, and ligated 
into PX330 plasmid which co-expresses Cas9 and sgRNA. This process proved to be simple and 
highly economical; two features that make it portable to high content screens. This raises the 
prospect that large-scale, custom-designed CRISPR knockout libraries could be quickly and 
inexpensively created. 
A second potential advantage is the prospect of multiplex screening, e.g. simultaneous 
knockdown of multiple target genes. It has been shown that in the presence of multiple sgRNAs, 
Cas nucleases can cleave diverse DNA sequences in the same cell (Cong et al., 2013). This 
strategy has been used to achieve multiplex knockdown in a variety of systems, including 
zebrafish, mouse embryonic stem cells, human immortalized myoblasts, HEK293T cells, and 
yeast (Jakociunas et al., 2015; Jao et al., 2013; Kabadi et al., 2014; Ousterout et al., 2015; Yang et 
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al., 2013). Notably, simultaneous knockdown of three proteins (DNMT1, DNMT3a, and 
DNMT3b) was recently demonstrated using a CRISPR approach in neurons (Swiech et al., 2015).  
Combined with the high economy of sgRNA production these studies pave the way for a 
combinatorial screening approach in which multiple genes are concurrently targeted for knockout.  
Third, future screening projects could take advantage of the precision of CRISPR gene 
targeting without the ensuing DNA disruption. This is because Cas nucleases can be rendered 
catalytically inactive and unable to cleave DNA while still maintaining the ability to bind specific 
genomic loci under the control of user-designed sgRNA. One simple example is the fusion of the 
transcriptional activation domain VP64 to dCas9 to create a tool for targeted upregulation of 
specific genes (Perez-Pinera et al., 2013). The practical applications of targeted gene 
manipulation are nearly limitless and include the possibility of performing simultaneous, 
combinatorial knockout and overexpression screening. 
Finally, CRISPR-mediated knockout has now been demonstrated to be highly effective in 
CNS neurons in vivo. Although the large size of the spCas9 enzyme can present challenges to 
viral delivery, strategies to circumvent this problem are being developed. For instance, the use of 
smaller Cas9 family members or transgenic animals that conditionally express spCas9 are proving 
to be effective (Cong et al., 2013; Ran et al., 2015). Viral delivery of multiple sgRNA may 
therefore represent a rapid and flexible alternative to current transgenic approaches to achieving 
simultaneous knockout of multiple genes. Moreover, transgenic animals with constitutively 
expressed Cas9 will likely be useful as a source of cells for in vitro screening by simplifying 
sgRNA delivery and perhaps accelerating the onset of knockdown by eliminating the lag between 
transfection and Cas9 expression. It is clear that axon regeneration is regulated by many 
interacting genes and combinatorial gene manipulations have proven most effective in promoting 
growth (Belin et al., 2015; Jin et al., 2015; Sun et al., 2011). Thus the prospect exists that 
CRISPR-based approaches may accelerate both in vitro discovery of gene interactions that 
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regulate axon growth, and the transition to combinatorial testing of lead hits in vivo. Overall it is 
clear that CRISPR-based approaches have enormous potential to expand understanding of 
interactive gene function in a variety of cell types. In this context, the current demonstration of 
CRISPR efficacy and compatibility with high content screening in cultured CNS neurons is a 
promising indicator that this potential can be harnessed for neuroscience research. 
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III. METHODOLOGY 
 
Cloning and plasmid preparation 
pX330-U6-Chimeric_BB-CBh-hSpCas9 was a gift from Feng Zhang (Addgene plasmid # 
42230). The targeting sequence for NeuN was taken from (Platt et al., 2014). Targeting sequences 
for PTEN were designed using the publicly available Benchling CRISPR design tool 
(http://www.benchling.com). The overhang ‘CACC’ was added to the 5’ end of the two sgRNA 
sequences with the highest on-target score and the overhang ‘CAAA’ was added to the 5’ end of 
the reverse complements of these sequences. Anti PTEN sequences were 
GGTGGGTTATGGTCTTCAAA (PTEN A), TTTCCTGCAGAAAGACTTGA (PTEN B), 
CACCGGTTTGATAAGTTCTAGCTG (PTEN C), and CACCGTTTGTGGTCTGCCAGCTAA 
(PTEN D). The anti-NeuN sequence was CAGCAGCCCAAACGACTACAT, and the non-
targeting control sequence was GGGTCTTCGAGAAGACCTGT. Oligonucleotides of the 
targeting sequences and reverse complements with overhangs were ordered from ThermoFisher 
and annealed. Bbs1 enzyme was used to digest the PX330 plasmid and the annealed 
oligonucleotides were ligated into the cut backbone using T4 ligase as described in (Cong et al., 
2013). The PX330 plasmid containing sgRNA targeting sequences were then transformed into E. 
cloni Chemically Competent Cells (VWR 95040-456) and DNA was prepared by QIAprep Spin 
Miniprep Kit (Qiagen 27106). The reporter plasmid expressed EBFP-2A-H2B-EGFP from a CMV 
promoter, and was constructed by replacing the 2A-mCherry sequence from a reporter previously 
described in (Wang et al., 2015) with EGFP fused to H2B to drive nuclear localization. 
 
Cortical cell dissociation, transfection, and culture 
All animal procedures were approved by the Marquette University Institutional Animal 
Care and Use Committee. Cortical neurons were prepared from early postnatal (P3–P5)Sprague 
Dawley rat pups (Charles River) and transfected as in Blackmore et al., 2010. Frontal cortices were 
placed in ice-cold Hibernate E (Life Technologies A12476-01), their meninges removed, finely 
minced and transferred into 10 ml dissociation media for 30 min at 37 °C with constant shaking 
(Hibernate E containing 20 U/ml papain (Worthington 3126) and 2.5 μg/ml DNAse (Sigma 
D4527)). Cells were then rinsed with Hibernate E + 2% SM1, then rinsed in Hibernate E (no SM1), 
and incubated 30 min at 37 °C with constant shaking in 10 ml trypsin solution (Hibernate E 
containing 0.25% trypsin (Invitrogen/Gibco 15,090–046) and 2.5 μg/ml DNAse (Sigma D4527)). 
Cells were centrifuged (1 min, 10g), washed with Hibernate E+ 2% SM1, and triturated three times 
in 1.5 ml Hibernate E+ 2% SM1 containing 2 μl DNAse (Sigma D4527). The suspension was 
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allowed to settle for 2 min and the supernatant was collected; these steps were repeated until no 
cell pellet was visible. This process typically yielded 2 million cells/mL in 6-7 ml Hibernate E. For 
transfection, cortical neurons were centrifuged (4 min, 80g) and resuspended to 2 × 106 cells/ml in 
Internal Neuronal Buffer (INB) (KCl 135 mM, CaCl2 0.2mM, MgCl2 2mM, HEPES 10 mM, 
EGTA 5 mM, pH 7.3). 25 μl were placed into wells of a 96-well electroporation plate (BTX 
Harvard Apparatus 45–0450) and mixed with 25 μl of INB containing 1 μg EGFP plasmid and 4 
μg test plasmid. A 350 V, 300 μs pulse was delivered to each well by an ECM square wave pulse 
generator (Harvard Apparatus ECM-830) attached to a plate handler (BTX Harvard Apparatus HT-
200). After electroporation each well received 100 μl of Hibernate E. For short-term cell culture 
experiments, 10,000 cells/well, or for long-term cell culture experiments 100,000 cells/well, were 
placed in 24-well plates (Greiner Bio-One 662,160) pre-coated with 100 μg/ml poly-D-lysine 
hydrobromide (Sigma P7886) (N12 h, 37 °C), followed by 10 μg/ml laminin (Sigma L2020) (N2 
h, 37 °C). Cells were maintained at 37 °C, 5% CO2 in Enriched Neurobasal (ENB) media, modified 
from (Meyer-Franke et al., 1995), consisting of Neurobasal A (Invitrogen 10,888–022), 50X 
NeuronCult SM1 Neuronal Supplement (Stemcell Technologies 5711), 1 mM sodium pyruvate 
(Invitrogen 11360-070), 2 mM GlutaMAX (Invitrogen/Gibco 35050-061), 50 U/ml Penicillin–
Streptomycin (Invitrogen 15070-063), 5 μM Forskolin (Sigma F6886),  
To enrich for neurons in cultures maintained for longer than 3 days, 100 nM 5-Fluoro-2’-
deoxyuridine (FuDR) (Sigma-Aldrich F0503) was added to each well 1 day post-transfection. To 
facilitate long-term survival the media was replaced every 3 days, with fresh cortical media in the 
replating experiments and with FuDR-containing media in the time course experiments. 
 
Cortical cell culture replating 
Primary cortical neurons were transfected and cultured as previously described (Blackmore 
et al., 2010). Wells were rinsed twice with 400 µl of Hibernate E and then incubated for 10 minutes 
at 37 °C in 400 µl of StemPro Accutase Cell Dissociation Reagent (ThermoFisher A1110501). 
Accutase was then diluted with 400µl of fresh cortical media, cells were detached by pipetting three 
times, with half the well volume aspirated and dispensed each time.  Dissociated cells collected by 
centrifugation (4min, 80G). Cells were resuspended in one mL, counted, and plated at 10,000/well 
in 24-well plates (Greiner Bio-One 662,160) pre-coated with PDL/laminin using conditioned media 
from the original plate. Replated cells were fixed after 24 hours in 4% PFA.  
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Cortical cell culture immunohistochemistry and quantification 
Cultures were fixed in 4% paraformaldehyde (Electron Microscopy Sciences 15710) for 
30 min at room temperature, rinsed five times, blocked and permeabilized (PBS, 20% goat serum 
(Invitrogen 16210- 064), 0.2% Triton X-100 (G-Biosciences 786-513) for 30 min at room 
temperature, and incubated in primary antibody solution (PBS, 10% goat serum, 0.2% Triton X-
100, primary antibodies: rabbit anti-βIIItubulin (1:500, Sigma T2200), mouse anti-NeuN (1:500, 
Millipore MAB377), rabbit anti-PTEN (1:500, Cell Signaling 138G6) (overnight, 4 °C). After five 
washes, cultures were incubated in secondary antibody solution containing DAPI nuclear stain 
(PBS, 10% goat serum, 0.2% Triton X-100, 300 nM DAPI, dilactate (molecular probes D3571) 
secondary antibodies: Alexa Fluor 647 goat anti-rabbit IgG (1:500, Invitrogen A-21245), Alexa 
Fluor 546 goat anti-mouse IgG (1:500, Invitrogen A-11003)) for 2 h at room temperature. Plates 
were washed five times, and left in 1 ml PBS for imaging. 
For the time course of PTEN knockdown experiments, a fluorescent inverted microscope 
was used to identify EGFP + NeuN + cells as transfected neurons. For the time course of NeuN 
knockdown experiments, a fluorescent inverted microscope was used to identify EGFP + ΒIII-
tubulin + cells as transfected neurons. A circle was drawn around the cell body of each transfected 
cell and the fluorescence level of either NeuN or PTEN staining was recorded as quantified by NIS-
Elements Basic Research software. For all treatments and time points n = 40 transfected cells. 
Statistical analysis was paired t-test using Graphpad Prism Software. 
 
Neurite outgrowth analysis  
For neurite outgrowth assays, Cellomics Cell Insight NXT (Thermo Scientific) acquired 
images of 3 channels: nuclei (DAPI), neurite staining (βIII-tubulin), and reporter (EGFP), and 
Cellomics Scan v6.4.0 (Thermo Scientific) traced neurites and quantified reporter intensity. 
Average total neurite length was quantified for the 10% of cells with greatest EGFP intensity per 
plate (n > 100 cells per treatment). Average neurite length was normalized to PX330 non-target 
control for each plate. Each treatment was tested at least three times. Statistical analysis was paired 
t-test using Graphpad Prism Software. 
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IV. CONCLUSION 
The aim of this thesis was to determine the utility of CRISPR-mediated gene knockout 
for high content screening in primary cultures of cortical neurons. This technique has been 
applied in other systems to perform high content screens, but has never been tested in primary 
neurons.  We first showed that CRISPR/Cas9 is an effective means of selectively knocking down 
proteins of interest in primary neurons. We then optimized the technique for use in our high 
content screening platform to test the function of endogenously expressed genes through targeted 
knockout. This included determining the time course of protein knockout, devising a strategy for 
replating following an extended time in culture, and performing some initial neurite outgrowth 
experiments to provide a positive control for future studies.  In this work, I have shown that the 
CRISPR/Cas9 system can be effectively harnessed as a knockout tool in primary cortical neurons 
as well as our high content screening platform. 
We have previously performed overexpression screens in primary cortical neurons with 
great success. In one of our previous screens we focused on transcription factors that are 
dysregulated in cancerous states and found significant effects on neurite outgrowth through 
overexpression of 9 out of 69 genes tested – a hit rate of 13 percent (Simpson et al., 2015). 
However, since we used overexpression methods in these previous screens it is difficult to make 
conclusions about the efficacy of manipulating these genes in vivo. One reason for this is that 
exogenous introduction of a gene could have unforeseen effects if the system does not inherently 
express that gene product. Knockdown screens are required to test the necessity of endogenously 
expressed genes and studies have previously used methods such as RNAi and TALENs to test the 
necessity of gene expression. Unfortunately, these tools have several limitations that prevent their 
wide applicability in high content screens using primary neurons (Bridge et al., 2003; Sledz et al., 
2003). 
37 
 
 
This work builds upon previously published research in several ways. First, 
CRISPR/Cas9 is becoming a popular tool which has been tested in the neurons of living animals 
through the delivery of viral vectors ((Platt et al., 2014; Straub et al., 2014; Swiech et al., 2015; 
Zuckermann et al., 2015). To our knowledge, this study provides the first example of utilizing 
CRISPR/Cas9 through plasmid delivery to produce targeted, specific gene knockout in cultures of 
primary cortical neurons. Second, this study also provides a platform to test the necessity of genes 
that have been previously discovered through sufficiency screens. In addition, we hope that this 
newly optimized tool can discover the endogenous functions of genes that overexpression screens 
could not test. Finally, this work provides in vitro evidence to support the idea that the mTOR 
pathway, and specifically PTEN, plays an important role in the control of neurite outgrowth. 
Overall, this work has made several contributions to the spinal cord injury field and literature, 
which is evidenced by the publication that arose from this study (Callif et al., 2017). 
Although this research made a clear contribution to the literature there are still some 
limitations of the results. One major limitation of this study is that all the experiments were 
performed using cortical neurons, so the results may not be generalizable to neurons harvested 
from other brain regions. Another problem with this work is the extended time in culture required 
for effective CRISPR/Cas9-mediated knockout. This timing restriction could make it difficult to 
utilize this knockout screening platform as a flexible model of development. To overcome some 
of the other limitations of this extended culture time we developed a method of replating these 
post-mitotic neurons. Although replating the cells works well for analyzing neurite outgrowth 
after a week in culture, many of the cells die during this procedure. This likely introduces some 
selection into the experiments, since the final assay can only provide data about the growth of 
cells that survived the replating. It may end up that this selection pressure more accurately models 
growth after an injury, but only more experiments will be able to determine that.  
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Despite the limitations, these findings imply that a CRISPR/Cas9-based knockout 
strategy for neurite outgrowth screens is possible in primary cortical neurons. In this study, we 
provide data showing that PTEN knockout can be used to enhance growth (Callif et al., 2017). 
Future studies can make use of this information to run high content screens with a verified 
positive control. Performing a full-scale screen on hundreds of genes will be the immediate next 
step, but this platform provides many other avenues of research to explore. The CRISPR/Cas9 
system is rapidly becoming a flexible, modular tool that can be used for much more than simple 
genetic knockouts. There are studies which have used a catalytically inactive Cas9 (dead Cas9; or 
dCas9) to achieve a variety of other goals. For example, by fusing dCas9 to transcription factor 
activation or repression domains it is possible to modify gene expression without disrupting the 
underlying nucleotide sequence (Perez-Pinera et al., 2013). As another example of the flexibility 
of this technique, several groups have used dCas9 fusion proteins to manipulate the epigenetic 
environment of specific genes (Choudhury et al., 2016). Finally, there is research which suggests 
that dCas9 can even be tagged with a fluorescent molecule and exported into the cytoplasm where 
it can track mRNA molecules in real-time (Nelles et al., 2016). The optimization of these 
techniques may be far in the future, but they show that the platform we have created opens the 
doors to a wide range of possibilities. Furthermore, the applications of CRISPR/Cas9 extend in 
vivo, which provides an efficient and straightforward way to take the genes discovered through 
screening and apply them directly to a functional model of spinal cord injury. 
 This work has been an amazing experience. I feel that I have been a productive member 
of both the Blackmore lab and the spinal cord injury field. In the lab I performed a high content 
overexpression screen which resulted in a publication and the discovery of a role for HHEX in the 
developing brain. A hopeful avenue for future studies is to determine the specific mechanisms of 
action for the inhibitory effect of HHEX in growing neurons. Within the field I have developed a 
novel CRISPR/Cas9 knockout screening platform which is compatible with the use of primary 
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cortical neurons.  This includes a replating technique, which has been developed for peripheral 
neurons like dorsal root ganglion, but has never been accomplished for central nervous system 
neurons. Overall, I feel as though I have made a reasonable contribution to the field and I am 
proud of this work and the productivity I have achieved over the last several years. I look forward 
to seeing the future of the spinal cord injury field and how others can build on my work. 
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